Eloxx Pharmaceuticals Q2 EPS $(1.96) Misses $(1.54) Estimate
Portfolio Pulse from Happy Mohamed
Eloxx Pharmaceuticals reported Q2 losses of $1.96 per share, missing the analyst consensus estimate of $1.54 by 27.27%. This represents a 1533.33% increase in losses compared to the same period last year.
August 14, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eloxx Pharmaceuticals' Q2 earnings missed analyst estimates by 27.27%, with losses increasing significantly compared to last year.
Eloxx Pharmaceuticals reported a significant increase in losses for Q2, missing analyst estimates. This negative earnings report is likely to negatively impact investor sentiment and could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100